U.S., May 21 -- ClinicalTrials.gov registry received information related to the study (NCT06979674) titled 'Study of ESG406 in Adults With Solid Tumors' on May 13.
Brief Summary: This study is an open-label, dose-escalation and cohort expansion Phase I study, aiming to evaluate the safety, tolerability, PK characteristics and preliminary efficacy of ESG406, and determine the MTD, RP2D and administration regimens of ESG406. The study includes the dose escalation study in Phase Ia and the cohort expansion study in Phase Ib.
Study Start Date: June, 2025
Study Type: INTERVENTIONAL
Condition:
Locally Advanced/Metastatic Solid Tumors
Intervention:
DRUG: ESG406
Administered via intravenous (IV) infusion.
Recruitment Status: NOT_YET_RECRUI...